
Latest Data for Managing
ALK+ NSCLC Patients
Expert perspectives from Prof Ahn
Prof Myung-Ju Ahn speaks about the unmet medical needs, challenges and treatment selection in different settings based on recent data from four studies, with a focus on Asian populations.
ALK(+): anaplastic lymphoma kinase (positive); NSCLC: non-small-cell lung cancer.